
Active Fibroblast Growth Factor 19 (FGF19)

Catalog#:PHH12878

概述（Summary）

纯度（Purity）	Greater than 90% as determined by reducing SDS-PAGE.
内毒素（Endotoxin level）	Please contact with the lab for this information
蛋白构建（Construction）	【Leu25-Lys216】
Accession #	O95750
表达宿主（Host）	293F
种属（Species）	Homo sapiens (Human)
预测分子量（Predicted MW）	23.0 kDa
制剂（Form）	Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
运输方式（Shipping）	The product is shipped with ice bag. Upon receipt, store it immediately at the temperature listed below.
稳定性&储存（Stability &Storage）	12 months at -20°C to -80°C in lyophilized state.6 months at -20°C to -80°C under sterile conditions after reconstitution.7-10 days at 2°C to 8°C under sterile conditions after reconstitution.Please minimize freeze-thaw cycles.
复溶（Reconstitution）	Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
背景介绍（References）	Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4.

电泳图（SDS-PAGE image）



Greater than 90% as determined by reducing SDS-PAGE.

活性图（Bioactivity image）




Figure 1. The binding activity of FGF19 with FGFR4

Fibroblast Growth Factor 19 (FGF19) is a member of the fibroblast growth factor (FGF) family. FGF19 has important roles as a hormone produced in the ileum in response to bile acid absorption, regulates new bile acid synthesis, acting through the FGFR4/Klotho-β receptor complexes in the liver to inhibit CYP7A1. FGF19 also has metabolic effects, affecting glucose and lipid metabolism. Besides, Fibroblast Growth Factor Receptor 1 (FGFR4) has been identified as an interactor of FGF19, thus a binding ELISA assay was conducted to detect the interaction of recombinant human FGF19 and recombinant human FGFR4. Briefly, FGFR4 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 µl were then transferred to FGF19-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-FGFR4 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of FGF19 and FGFR4 was shown in Figure 1, and this effect was in a dose dependent manner, the EC50 was approximately 0.016 ug/mL.

注意事项（Note）

For Research Use Only , Not for Diagnostic Use.